Literature DB >> 15365145

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

Roelien H Enting1, Alexis Demopoulos, Lisa M DeAngelis, Lauren E Abrey.   

Abstract

The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15365145     DOI： 10.1212/01.wnl.0000137050.43114.42

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  65 in total

1.  Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

Authors:  Jorg Dietrich; Laura Versmee; Jan Drappatz; April F Eichler; Lakshmi Nayak; Andrew Norden; Eric Wong; Michelle R Pisapia; SooAe S Jones; Amanda B Gordon; Bruce A Chabner; Fred Hochberg; Tracy T Batchelor
Journal:  Oncologist       Date:  2020-07-01

2.  Primary CNS lymphoma.

Authors:  Uwe Schlegel
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

3.  Neuro-oncology in a nutshell.

Authors:  Joachim M Baehring
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule.

Authors:  M Santisteban; Y Nieto; S De la Cruz; J Aristu; J L Zubieta; O Fernández Hidalgo
Journal:  Clin Transl Oncol       Date:  2007-07       Impact factor: 3.405

Review 5.  Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?

Authors:  Jerome J Graber; Antonio Omuro
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

6.  Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

Authors:  T T Batchelor; S A Grossman; T Mikkelsen; X Ye; S Desideri; G J Lesser
Journal:  Neurology       Date:  2011-03-08       Impact factor: 9.910

7.  Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.

Authors:  Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-03-01       Impact factor: 4.130

8.  Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.

Authors:  Elisa J Pulczynski; Outi Kuittinen; Martin Erlanson; Hans Hagberg; Alexander Fosså; Mikael Eriksson; Marie Nordstrøm; Bjørn Østenstad; Øystein Fluge; Sirpa Leppä; Bente Fiirgaard; Hanne Bersvendsen; Unn-Merete Fagerli
Journal:  Haematologica       Date:  2014-12-05       Impact factor: 9.941

9.  Primary central nervous system lymphoma.

Authors:  Stephane Doucet; Priya Kumthekar; Jeffrey Raizer
Journal:  Curr Treat Options Oncol       Date:  2013-06

10.  Rituximab in the treatment of non-Hodgkin's lymphoma.

Authors:  Beate Hauptrock; Georg Hess
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.